Cushing's syndrome variants secondary to aberrant hormone receptors

被引:76
作者
Lacroix, A [1 ]
Baldacchino, V
Bourdeau, I
Hamet, P
Tremblay, J
机构
[1] Univ Montreal, Hop Hotel Dieu, Dept Med, Lab Endorcine Pathophysiol, Montreal, PQ H2W 1T8, Canada
[2] Univ Montreal, Hop Hotel Dieu, Dept Med, Lab Cellular Biol Hypertens, Montreal, PQ H2W 1T8, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.tem.2004.08.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The secretion of cortisol and other steroids from adrenal tumors can be regulated by hormones other than corticotropin following the aberrant expression of several G-protein-coupled receptors (GPCRs). To date, ectopic receptors for gastric inhibitory polypeptide, beta-adrenergic receptor agonists, vasopressin V-2 and V-3 receptors), 5-hydroxytryptamine (5-HT7 receptor) and, probably, angiotensin II (AT, receptor) have been identified. Either increased expression or altered activity of eutopic receptors for vasopressin (V-1), luteinizing hormone/human chorionic gonadotropin, 5-HT (5-HT4 receptor) and leptin might also be involved. One or more aberrant receptors can be present in unilateral tumors and bilateral macronodular adrenal hyperplasia, at either the early subclinical or overt stages of hormone secretion. The identification of aberrant adrenal GPCRs offers the potential for novel pharmacological therapies that either suppress the endogenous ligands or block the receptor with specific antagonists.
引用
收藏
页码:375 / 382
页数:8
相关论文
共 70 条
[1]   Analysis of the putative regulatory region of the gastric inhibitory polypeptide receptor gene in food-dependent Cushing's syndrome [J].
Antonini, SR ;
N'Diaye, N ;
Baldacchino, V ;
Hamet, P ;
Tremblay, J ;
Lacroix, A .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 91 (03) :171-177
[2]   Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors [J].
Arnaldi, G ;
Gasc, JM ;
de Keyzer, Y ;
Raffin-Sanson, ML ;
Perraudin, V ;
Kuhn, JM ;
Raux-Demay, MC ;
Luton, JP ;
Clauser, E ;
Bertagna, X .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) :2029-2035
[3]  
BALDACCHINO V, 2003, END SOC 85 M JUN 18, P446
[4]   Aberrant receptor-mediated Cushing's syndrome [J].
Bertagna, X ;
Groussin, L ;
Luton, JP ;
Bertherat, J .
HORMONE RESEARCH, 2003, 59 :99-103
[5]  
BERTHERAT J, 2003, END SOC 85 M PHIL PA, P570
[6]  
Bertherat J., 2004, END SOC 86 M JUN 16, P562
[7]   Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators [J].
Bourdeau, I ;
Antonini, SR ;
Lacroix, A ;
Kirschner, LS ;
Matyakhina, L ;
Lorang, D ;
Libutti, SK ;
Stratakis, CA .
ONCOGENE, 2004, 23 (08) :1575-1585
[8]   Primary Pigmented nodular adrenocortical disease:: Paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor [J].
Bourdeau, I ;
Lacroix, A ;
Schürch, W ;
Caron, P ;
Antakly, T ;
Stratakis, CA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08) :3931-3937
[9]   Cyclic AMP-dependent signaling aberrations in macronodular adrenal disease [J].
Bourdeau, I ;
Stratakis, CA .
PROTEIN KINASE A AND HUMAN DISEASE, 2002, 968 :240-255
[10]   Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome [J].
Bourdeau, I ;
D'Amour, P ;
Hamet, P ;
Boutin, JM ;
Lacroix, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (11) :5534-5540